Browse our anti-TRIM29 (TRIM29) Antibodies

Human Tripartite Motif Containing 29 (TRIM29) interaction partners

1. Knockdown of tripartite motif-containing 29 protein (TRIM29) enhanced the production of type I interferon (show IFNA Antibodies) in human and mouse dendritic cells by up to fourfold in response to intracellular herpes simplex virus.

2. the current study demonstrated that TRIM29 upregulates cyclin (show PCNA Antibodies) and Bcl family proteins level to facilitate malignant cell growth and inhibit drug-induced apoptosis in bladder cancer, possibly through PKC (show PRRT2 Antibodies)-NF-kappaB (show NFKB1 Antibodies) signaling pathways.

3. High TRIM29 expression is associated with metastasis of nasopharyngeal carcinoma.

4. Data show that TRIM29 promotes tumor progression by activating Wnt (show WNT2 Antibodies)/beta-Catenin (show CTNNB1 Antibodies) signaling.

5. This study establishes TRIM29 as a hypoxia-induced tumor suppressor gene and provides a novel molecular mechanism for ATM (show ATM Antibodies)-dependent breast cancer suppression.

6. Upregulation of TRIM29 is associated with thyroid cancer.

7. miR (show MLXIP Antibodies)-761 acts as an oncogene (show RAB1A Antibodies) in triple-negative breast cancer. This mode of action can, at least partially, be ascribed to the down-regulation of its target TRIM29.

8. Silencing of TRIM29 significantly inhibited the migration and invasion ability of CRC (show CALR Antibodies) cells.

9. Findings established a role for ATDC/TRIM29 as a robust pathogenic driver of bladder cancer development, identified downstream effector pathways, and implicated ATDC as a candidate biomarker and therapeutic target.

10. define a novel function for ATDC in the RNF8 (show RNF8 Antibodies)-mediated DNA damage response and implicate RNF8 (show RNF8 Antibodies) binding as a key determinant of the radioprotective function of ATDC

Mouse (Murine) Tripartite Motif Containing 29 (TRIM29) interaction partners

1. Knockdown of tripartite motif-containing 29 protein (TRIM29) enhanced the production of type I interferon (show IFNA Antibodies) in human and mouse dendritic cells by up to fourfold in response to intracellular herpes simplex virus.

2. this study shows that deletion of TRIM29 enhanced macrophage production of type I interferons and protected mice from infection with influenza virus, while challenge of Trim29-/- mice with Haemophilus influenzae resulted in lethal lung inflammation due to massive production of proinflammatory cytokines by macrophages

3. Findings established a role for ATDC/TRIM29 as a robust pathogenic driver of bladder cancer development, identified downstream effector pathways, and implicated ATDC as a candidate biomarker and therapeutic target.

4. ATDC up-regulates CD44 (show CD44 Antibodies) in mouse and human PanIN lesions via activation of beta-catenin (show CTNNB1 Antibodies) signaling, leading to the induction of an epithelial-to-mesenchymal transition (EMT (show ITK Antibodies)) phenotype characterized by expression of Zeb1 (show ZEB1 Antibodies) and Snail1 (show SNAI1 Antibodies).

5. Histone deacetylase 9 (HDAC9 (show HDAC9 Antibodies)) regulates the functions of the ATDC (TRIM29) protein

6. ATDC increases cell proliferation via inhibition of p53 (show TP53 Antibodies) nuclear activities.